Allarity Therapeutics, Inc. ALLR

ALLR Company Overview

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company focused on developing personalized cancer therapeutics. The company operates within the biotechnology and oncology sectors, with an emphasis on using drug-specific predictive biomarkers to identify patients most likely to benefit from targeted cancer treatments. Its business model combines therapeutic development with companion diagnostic technologies intended to improve clinical response rates and reduce ineffective treatment exposure in oncology care.

The company’s primary assets have historically included oncology drug candidates and its proprietary Drug Response Predictor (DRP®) technology platform, which uses gene expression data to predict patient response to specific therapies. Allarity has pursued development programs in indications including ovarian cancer and other solid tumors. The company evolved from earlier Scandinavian biotechnology operations and later established a U.S.-listed corporate structure. Over time, it repositioned toward precision oncology and biomarker-guided drug development through acquisitions, licensing arrangements, and internal clinical research initiatives.